- Home
- CRIS vs GRCE Comparison
CRIS vs GRCE Comparison
Compare CRIS & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- GRCE
- Stock Information
- Founded
- CRIS 2000
- GRCE 2002
- Country
- CRIS United States
- GRCE United States
- Employees
- CRIS N/A
- GRCE N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- GRCE
- Sector
- CRIS Health Care
- GRCE
- Exchange
- CRIS Nasdaq
- GRCE NYSE
- Market Cap
- CRIS 27.5M
- GRCE 30.9M
- IPO Year
- CRIS 2000
- GRCE N/A
- Fundamental
- Price
- CRIS $3.87
- GRCE $4.00
- Analyst Decision
- CRIS Strong Buy
- GRCE
- Analyst Count
- CRIS 3
- GRCE 0
- Target Price
- CRIS $23.00
- GRCE N/A
- AVG Volume (30 Days)
- CRIS 238.7K
- GRCE 74.7K
- Earning Date
- CRIS 02-06-2025
- GRCE 01-14-2025
- Dividend Yield
- CRIS N/A
- GRCE N/A
- EPS Growth
- CRIS N/A
- GRCE N/A
- EPS
- CRIS N/A
- GRCE N/A
- Revenue
- CRIS $10,259,000.00
- GRCE N/A
- Revenue This Year
- CRIS N/A
- GRCE N/A
- Revenue Next Year
- CRIS N/A
- GRCE N/A
- P/E Ratio
- CRIS N/A
- GRCE N/A
- Revenue Growth
- CRIS 0.44
- GRCE N/A
- 52 Week Low
- CRIS $2.86
- GRCE $1.98
- 52 Week High
- CRIS $17.49
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- CRIS 53.89
- GRCE N/A
- Support Level
- CRIS $2.86
- GRCE N/A
- Resistance Level
- CRIS $4.50
- GRCE N/A
- Average True Range (ATR)
- CRIS 0.39
- GRCE 0.00
- MACD
- CRIS 0.09
- GRCE 0.00
- Stochastic Oscillator
- CRIS 61.59
- GRCE 0.00
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.